• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Liver international >The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease
【24h】

The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease

机译：The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相关主题

摘要

Abstract Background and aims Non‐O blood type (BT) is a risk factor for thromboses, which has been attributed to its effects on von Willebrand factor (VWF)/factor VIII (FVIII) levels. Although high VWF/FVIII may be risk factors for portal vein thrombosis (PVT) in patients with advanced chronic liver disease (ACLD), the impact of BT on PVT is unknown. We aimed to assess (I) whether non‐O‐BT is a risk factor for PVT and (II) whether non‐O‐BT impacts VWF/factor VIII in patients with ACLD. Methods Retrospective analysis comprising two cohorts: (I) “ US ” including all adult liver transplantations in the US in the MELD era and (II) “ Vienna ” comprising patients with a hepatic venous pressure gradient (HVPG) ≥6?mmHg. Results (I) The “ US cohort ” included 84?947 patients (non‐O: 55.43%). The prevalence of PVT at the time of listing (4.37% vs 4.56%; P ?=?.1762) and at liver transplantation (9.56% vs 9.33%; P ?=?.2546) was similar in patients with O‐ and non‐O‐BT. (II) 411 patients were included in the “Vienna cohort” (non‐O: 64%). Mean HVPG was 18(9) mmHg and 90% had an HVPG ≥10?mmHg. Patients with non‐O‐BT had slightly increased VWF levels (318(164)% vs 309(176)%; P ?=?.048; increase of 23.8%‐23.9% in adjusted analyses), but this difference was driven by patients with less advanced disease. However, non‐O‐BT explained only 1% of the variation in VWF and had no effect on FVIII. Conclusions Although non‐O‐BT impacts VWF in patients with early stage ACLD, its contribution to VWF variation is considerably smaller than in the general population. Moreover, non‐O‐BT had no impact on FVIII. These findings may explain the absence of an association between non‐O‐BT and PVT in patients with advanced cirrhosis.

著录项

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号